121results about "Osmotic delivery" patented technology

The invention discloses a conical asymmetric nano robot for deep tumor penetration as well as a preparation method and application of the conical asymmetric nano robot. The structure of the asymmetric nano robot is Fe3O4 (at) mPDA (at) MnO2amp; mSiO2, and is marked as FPMamp; s; an FPMamp (Fabry Perot Module); the S nano-robot is nano-particles of an asymmetric structure, one end of the asymmetric structure is of a core-shell structure, the core is spherical Fe3O4, and the shell is mesoporous polydopamine particles; one end of the rod-like structure, which is far away from the Fe3O4, is conical; mnO2 is loaded on the surface of the mesoporous polydopamine; the asymmetric structure with the conical tail part is constructed, so that the forward wedging capability of the nano-robot in the moving process is improved, and the deep tumor penetrating performance is fundamentally improved; through the same nanorobot, collaborative treatment of multiple mechanisms of photo-thermal-Fenton-GSH depletion in space and time is achieved, the overall treatment efficiency of a deep tumor area is improved, and the problems that an existing asymmetric micro / nanorobot is insufficient in deep tumor penetrating capacity, the collaborative efficiency of a treatment module is limited and the like are solved.

The present invention provides for the immediate or chronic administration of certain potassium ATP (K ATP ) channel openers, optionally in combination with growth hormone, to subjects to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic, and compositional outcomes in the treatment of diseases or conditions involving K ATP channels. Also provided are pharmaceutical formulations, methods of administration, and methods of dosing K ATP channel openers to achieve these outcomes and to reduce the incidence of adverse effects in treated individuals. Also provided are methods of co-administering K ATP channel openers with other drugs, e.g., in combination with growth hormone, to treat diseases in humans and animals, e.g., Prader-Willi Syndrome (PWS), Smith-Magenis Syndrome (SMS), etc.

The present invention can provide: a colon purgation tablet having a gel-forming coating layer containing an alginate as a main component, the gel-forming coating layer being introduced into an uncoated tablet containing an osmotic substance, the present invention relates to an uncoated tablet, and more particularly, to an uncoated tablet, such that the osmotic substance contained in the uncoated tablet disintegrates rapidly while preventing damage to gastric mucosa due to a physical collision between the tablet and the gastric mucosa, and thus provides an excellent intestinal cleansing effect. The colon purgation tablet according to the present invention can exhibit an excellent intestinal cleansing effect even at a small dose, and can further improve drug compliance by selectively miniaturizing the tablet or introducing an adhesive to improve a coating layer.

An orifice-free drug delivery device is provided. In an embodiment, the device includes a body having at least one water-permeable wall bounding a reservoir defined within the body. A drug formulation is disposed within the reservoir. The body has an elastic portion and at least one restraining plug closing off an opening of the body. The opening is in fluid communication with the reservoir, and the restraining plug contacts the elastic portion of the body and controls release of the drug from the device by the transient formation of one or more microchannels between the elastic portion of the body and the at least one restraining plug. The elastic portion may define an opening having an inner diameter, which is exceeded by the outer diameter of the restraining plug by at least 3 %.

This invention relates to isolated polypeptides that are analogs of human amylin. The disclosed amylin analog polypeptides have beneficial physicochemical properties relative to endogenous amylin, such as longer elimination half-lives (t1 / 2) and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed amylin analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed amylin analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as types 1 and 2 diabetes, and providing weight loss.

To provide a medical device for controlled drug discharge including, but not limited to, a device that can be deployed in a bladder for discharging a drug into the bladder.SOLUTION: An implantable drug delivery device 200 includes: a housing 208 that defines a storage part 204; a first unit 202 inside the storage part; and a second unit 210 inside the storage part. The first unit 202 stores a drug. The second unit 210 stores a functional agent that promotes discharge of the drug. An intravesical drug delivery device 200 includes a housing 208 portion storing a drug preparation and a housing 208 portion storing an excipient, and is configured to discharge the drug according to a first discharge profile and discharge the excipient according to a second discharge profile. A method includes inserting any of these devices 200 to a patient, and discharging a drug from the device 200.SELECTED DRAWING: Figure 2

A method of producing an oral osmotic pharmaceutical delivery system by using a statistical modeling. The method includes determining a desired average dissolution profile for the active pharmaceutical ingredient; and controlling tablet strength, acetyl content of the cellulose acetate and weight gain of the semi-permeable membrane of the tablet to produce a pharmaceutical batch of tablets having the desired dissolution profile.

Provided herein are methods of treatment, erdafitinib for use and use of erdafitinib for the treatment of bladder cancer harboring one or more FGFR alterations comprising locally delivering erdafitinib into the bladder of a patient.

The present invention relates to a pharmaceutical composition for use in the treatment of both low-grade and high-grade glioblastoma in a human subject. The composition comprises a synergistic combination of the following active agents: R-Ketorolac, Bumetanide, and Niflumic acid. This specific combination is designed to exert a synergistic therapeutic effect against glioblastoma by targeting multiple molecular pathways involved in tumor progression, inflammation, and ion transport. In a further aspect of the invention, there is provided a method for selecting a subpopulation of glioblastoma subjects who are responsive to the aforementioned treatment. This method comprises identifying genetic profiles predictive of a favorable therapeutic response to the combined administration of R-Ketorolac, Bumetanide, and Niflumic acid.

The invention discloses a medicinal moxa composition for preventing and treating atherosclerosis and suppurative bacterial infection co-disease. The medicinal moxa composition comprises coptis chinensis, radix rehmanniae, polygala tenuifolia, juncus effuses and moxa. The medicinal folium artemisiae argyi composition disclosed by the invention can be used for effectively preventing and treating atherosclerosis and skin suppurative bacterial infection co-diseases through a multi-target synergistic effect. The medicinal moxa composition has the core effects of clearing away heart-fire, inducing diuresis for treating stranguria and promoting blood circulation to remove meridian obstruction, and forms a complete treatment system which uses cold and warm as well as treats both symptoms and root causes by purging fire for removing toxin through coptis chinensis, clearing heat and cooling blood through radix rehmanniae, soothing nerves and promoting intelligence through polygala, inducing diuresis and conducting heat downward movement through juncus effuses and combining moxa floss for warming and dredging meridians, eliminating cold to stop pain, resisting bacteria and diminishing inflammation. By inhibiting inflammatory factors, regulating epithelial cell proliferation and reaction to oxidative stress, regulating fluid shear force, atherosclerosis and Kaposi sarcoma-related herpesvirus infection-related pathways and other mechanisms, the medicinal folium artemisiae argyi composition realizes synergistic prevention and treatment of atherosclerosis and skin infection, and provides a basis for co-disease treatment.

The disclosure relates generally to methods of treating central nervous system disorders using (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane (i.e. centanafadine) or a pharmaceutically acceptable salt thereof. More particularly, the disclosure relates to treating conditions affected by monoamine neurotransmitters.

Drug delivery devices and methods of controlled drug delivery to a patient are provided. The drug delivery device may include one or two microchip elements, each of which has a body portion with one or more drug release apertures in fluid communication with at least one containment reservoir. The drug release apertures are closed off by one or more reservoir caps which can be electrically activated to open the drug release apertures. The drug delivery device also includes (i) a drug formulation disposed in the at least one containment reservoir, and (ii) at least one drug-permeable membrane. In some cases, an outer housing is spaced a distance from an exterior wall of the body portion of the microchip element, the outer housing includes the at least one drug-permeable membrane, and a depot space is defined between the drug-permeable membrane and the exterior wall of the body portion of the microchip element.

Disclosed is the use of orexin type 2 receptor (OX2R) agonists at non-wake concentrations. Also disclosed are compositions and methods for administering an OX2R agonist to a subject (e.g., a mammal) requiring such administration at a dose that keeps the plasma concentration of the OX2R agonist below the maximum non-wake plasma concentration of the OX2R agonist. Also disclosed are compositions and methods for treating narcolepsy type 1 (NT1) in a subject requiring such treatment by maintaining, after administration, the plasma concentration of the OX2R agonist below the maximum non-wake concentration of the OX2R agonist.

A film and a method for use thereof such as for the administration of a biologically active agent or for therapy are provided. Specifically, a film, composed of a biodegradable material having a mucoadhesive surface comprising a plurality of mushroom-type structures is provided.

An oral dosage form of an antidiabetic pharmaceutical composition comprises a metformin-containing core portion, an outer portion that comprises a non-biguanide antidiabetic agent such as sitagliptin, and a controlled membrane film sandwiched therebetween. The controlled membrane film is provided with at least one passageway allowing core-residing metformin to release out when the oral dosage form is in an aqueous environment, such as in the gastrointestinal (GI) tract of a subject. The oral dosage form has a dissolution profile such that upon dissolving in a medium with a pH of approximately 6.8 at approximately 37° C., less than 15% of the metformin is released at approximately 1 hours, and approximately 45-99% of the metformin is released at approximately 12 hours. The oral dosage form can provide a maximum plasma concentration of the metformin from approximately 7.5 to 15 hours after single-dose oral administration.

The present invention relates to an osmotic agent composition comprising an acid-sensitive polymer in a coating layer. More particularly, the present invention relates to an osmotic agent composition and a method for preparing same, the osmotic agent composition comprising an acid-sensitive polymer that can be dissolved or separated in an acidic condition so as to form a porous osmosis membrane on a coating layer of the osmotic agent composition.

A composition includes a salt; a polymer; and an antioxidant. A dispenser includes a flexible container having a closed end and an opposed open end; an osmotically-effective solute composition encapsulating at least a portion of the container, the solute composition including antioxidant in an amount of at least 0.5 wt%, based on weight of the solute composition; a semipermeable membrane encapsulating the osmotically-effective solute composition; a cap having a sealing surface adapted for sealing engagement with the open end of the container; and a port extending from an interior of the container and through the cap. Also disclosed are methods of making and using the composition and osmotic pumps.

The invention relates to a traditional Chinese medicine liquid and a traditional Chinese medicine ointment for expelling toxins from osteoporosis and a preparation method thereof. The traditional Chinese medicine liquid for expelling toxins from osteoporosis is prepared from the following raw materials in parts by weight: 10-15 parts of radix clematidis, 12-18 parts of trifid sopubia herb, 10-15 parts of garden balsam stem, 15-25 parts of suberect spatholobus stem, 6-10 parts of safflower, 9-12 parts of Chinese angelica, 6-8 parts of liquorice and 8-12 parts of folium artemisiae argyi. The preparation method of the bone seam detoxifying traditional Chinese medicine liquid comprises the following steps: a, pretreating the raw materials; b, decocting and extracting; c, filtering and concentrating; d, blending and homogenizing; and e, sterilizing and packaging. The traditional Chinese medicine liquid and the traditional Chinese medicine ointment for detoxifying the bone seams are particularly used for detoxifying toxins such as deep damp turbidity and phlegm stasis in the bone seams, and are suitable for relieving symptoms such as ankylosis, deep pain, hyperostosis and the like caused by deposition of toxins in the bone seams. The bone seam detoxification traditional Chinese medicine liquid and the traditional Chinese medicine ointment have the remarkable advantages of being high in seepage force, comprehensive in detoxification, high in safety, wide in applicability and the like.

The invention discloses an external medicine composition compress bag and a traditional Chinese medicine compound external medicine composition, and relates to the technical field of external medicine compositions and patches, the external medicine composition compress bag is used for manufacturing a traditional Chinese medicine compress bag aiming at breasts and related collateral breasts, axillary lymph nodes, axillary region skin and mammary gland related acupuncture points, the humanization is combined with the human body structure, and the traditional Chinese medicine compress bag is made. And all-directional application is realized. The external medicine composition compress bag comprises a compress bag body, the compress bag body is divided into a lymph node traditional Chinese medicine compress bag, a collateral breast and axilla area skin traditional Chinese medicine compress bag, a breast traditional Chinese medicine compress bag and a breast lower plica area traditional Chinese medicine compress bag through heat bonding partition lines, and each traditional Chinese medicine compress bag sequentially comprises an outer wrapping layer, a heating layer, a traditional Chinese medicine layer and an inner cotton cloth layer from outside to inside. The external use pharmaceutical composition compress bag can be used for household treatment and breast health care.

To provide a nonaqueous carbon dioxide external preparation in single dosage form.SOLUTION: An external preparation comprises a paste base, carbonate, an acid and / or a substance which produces an acid by hydrolysis, and alcohol. By applying the external preparation to the skin, it is possible to readily achieve the unique effects of carbon dioxide. This renders the preparation beneficial.SELECTED DRAWING: None

Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time.

The invention discloses a traditional Chinese medicine composition for assisting a tumor patient in warming yang, removing stasis and easing pain and a hot compress bag thereof, and relates to the technical field of external hot compress traditional Chinese medicines, the traditional Chinese medicine composition comprises the following raw materials: radix aconiti lateralis preparata, rhizoma zingiberis, fructus evodiae, pericarpium zanthoxyli, fennel, astragalus membranaceus, angelica sinensis, cinnamon, fried semen raphani and honey-fried licorice root. The traditional Chinese medicine formula takes the idea of strengthening yang as the core, follows the formula logic of strengthening yang to strengthen the root and eliminating evil without hurting healthy qi, accurately accords with the physical characteristics of'deficiency of healthy qi and stasis of evil toxin 'of tumor patients, directly strikes the core pathogenesis of'deficiency of yang-congealing cold-stasis toxin' of cancer patients through the compatibility of medicinal materials for warming and strengthening congenital kidney yang, warming and dredging meridian stasis, tonifying qi, nourishing blood and strengthening body resistance, and has a remarkable curative effect. The traditional Chinese medicine composition is capable of conditioning yang-deficiency constitution, realizing dual goals of relieving symptoms and improving constitution, preventing pathological vicious circle, enabling conditioning to be more fundamental, and avoiding the limitation that only surface symptoms are relieved and are not treated fundamentally.

The present invention provides drug delivery devices and methods for controlled drug delivery to a patient. The drug delivery devices can include one or two microchip elements, each having a body portion with one or more drug release apertures in fluid communication with at least one contained reservoir. The drug release apertures are closed by one or more reservoir covers that can be electrically activated to open the drug release apertures. The drug delivery devices further include (i) a drug formulation disposed in the at least one contained reservoir, and (ii) at least one drug permeable membrane. In some cases, an outer housing is spaced apart from an outer wall of the body portion of the microchip element, the outer housing includes the at least one drug permeable membrane, and defines a reservoir space between the drug permeable membrane and the outer wall of the body portion of the microchip element.

Disclosed herein are methods for otoprotection against platinum-based antineoplastic agents by administering a thiosulfate salt to a subject in need thereof. Typically, the thiosulfate salt is administered to the subject scheduled to be administered a platinum-based antineoplastic agent within 4 hours. Alternatively, the thiosulfate salt is administered within 7 hours after the administration of a platinum-based neoplastic agent.

To provide drug delivery devices and methods of controlled drug delivery to a patient.SOLUTION: A drug delivery device may include one or two microchip elements, each of which has a body portion with one or more drug release apertures in fluid communication with at least one containment reservoir. The drug release apertures are closed off by one or more reservoir caps which can be electrically activated to open the drug release apertures. The drug delivery device also includes (i) a drug formulation disposed in the at least one containment reservoir, and (ii) at least one drug-permeable membrane. In some cases, an outer housing is spaced a distance from an exterior wall of the body portion of the microchip element, the outer housing includes the at least one drug-permeable membrane, and a depot space is defined between the drug-permeable membrane and the exterior wall of the body portion of the microchip element.SELECTED DRAWING: Figure 2